These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 37262000)

  • 1. Evaluation of the Cherokee Nation Hepatitis C Virus Elimination Program - Cherokee Nation, Oklahoma, 2015-2020.
    Essex W; Feder M; Mera J
    MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(22):597-600. PubMed ID: 37262000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Clinical Management of Persons with Chronic Hepatitis C Virus Infection - Cherokee Nation, 2012-2015.
    Mera J; Vellozzi C; Hariri S; Carabin H; Drevets DA; Miller A; Reilley B; Essex W; Gahn D; Lyons L; Leston J; Ward JW
    MMWR Morb Mortal Wkly Rep; 2016 May; 65(18):461-6. PubMed ID: 27172175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Cherokee Nation Hepatitis C Virus Elimination Program in the First 22 Months of Implementation.
    Mera J; Williams MB; Essex W; McGrew KM; Boeckman L; Gahn D; Miller A; Durham D; Fox J; David C; Ritter T; Jones S; Bouse S; Galvani A; Ward JW; Drevets DA; Carabin H
    JAMA Netw Open; 2020 Dec; 3(12):e2030427. PubMed ID: 33337496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Feasibility, Acceptability, and Effectiveness of a Pilot Hepatitis C Screening Program at Food Distribution Sites in Cherokee Nation, Oklahoma.
    Essex W; Mera J; Comiford A; Winters A; Feder MA
    J Community Health; 2023 Dec; 48(6):982-993. PubMed ID: 37531046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Regional Analysis of Hepatitis C Virus Collaborative Care With Pharmacists in Indian Health Service Facilities.
    Geiger R; Steinert J; McElwee G; Carver J; Montanez R; Niewoehner J; Clark C; Reilley B
    J Prim Care Community Health; 2018; 9():2150132718807520. PubMed ID: 30348039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.
    Tsertsvadze T; Gamkrelidze A; Chkhartishvili N; Abutidze A; Sharvadze L; Kerashvili V; Butsashvili M; Metreveli D; Gvinjilia L; Shadaker S; Nasrullah M; Adamia E; Zeuzem S; Afdhal N; Arora S; Thornton K; Skaggs B; Kuchuloria T; Lagvilava M; Sergeenko D; Averhoff F
    Clin Infect Dis; 2020 Aug; 71(5):1263-1268. PubMed ID: 31563938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.
    Nasrullah M; Sergeenko D; Gvinjilia L; Gamkrelidze A; Tsertsvadze T; Butsashvili M; Metreveli D; Sharvadze L; Alkhazashvili M; Shadaker S; Ward JW; Morgan J; Averhoff F
    MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(29):773-776. PubMed ID: 28749925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
    Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
    J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.
    Gvinjilia L; Nasrullah M; Sergeenko D; Tsertsvadze T; Kamkamidze G; Butsashvili M; Gamkrelidze A; Imnadze P; Kvaratskhelia V; Chkhartishvili N; Sharvadze L; Drobeniuc J; Hagan L; Ward JW; Morgan J; Averhoff F
    MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(41):1132-1135. PubMed ID: 27764081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
    Seeff LB; Hoofnagle JH
    Clin Liver Dis; 2003 Feb; 7(1):261-87. PubMed ID: 12691470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
    Ioannou GN; Beste LA; Chang MF; Green PK; Lowy E; Tsui JI; Su F; Berry K
    Gastroenterology; 2016 Sep; 151(3):457-471.e5. PubMed ID: 27267053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia.
    Gamkrelidze A; Handanagic S; Shadaker S; Turdziladze A; Tsereteli M; Getia V; Aslanikashvili A; Surguladze S; Gvinjilia L; Kuchuloria T; Tskhomelidze I; Armstrong PA
    Public Health; 2022 Apr; 205():182-186. PubMed ID: 35305459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment.
    Liu CH; Peng CY; Kao WY; Yang SS; Shih YL; Lin CL; Tsai MK; Lee CY; Chang CC; Wu JH; Liu CJ; Su TH; Tseng TC; Chen PJ; Kao JH
    Aliment Pharmacol Ther; 2022 Feb; 55(4):434-445. PubMed ID: 34773272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort.
    Adland E; Jesuthasan G; Downs L; Wharton V; Wilde G; McNaughton AL; Collier J; Barnes E; Klenerman P; Andersson M; Jeffery K; Matthews PC
    BMC Infect Dis; 2018 Sep; 18(1):461. PubMed ID: 30217169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings.
    Ngo BV; James JR; Blalock KL; Jackson SL; Chew LD; Tsui JI
    J Subst Abuse Treat; 2021 Dec; 131():108438. PubMed ID: 34098298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals.
    Bartlett SR; Yu A; Chapinal N; Rossi C; Butt Z; Wong S; Darvishian M; Gilbert M; Wong J; Binka M; Alvarez M; Tyndall M; Krajden M; Janjua NZ
    Liver Int; 2019 Dec; 39(12):2261-2272. PubMed ID: 31444846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
    Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M
    Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.